Abstract
Plasminogen activator inhibitor type 1 (PAI-1) plays a key role in tumor progression and is believed to control proteolytic activity and cell migration during angiogenesis. We report here that host PAI-1, at physiological concentration, promotes in vivo tumor invasion and angiogenesis. In sharp contrast, inhibition of tumor vascularization was observed when PAI-1 was produced at supraphysiologic levels, either by host cells (transgenic mice overexpressing PAI-1) or by tumor cells (after transfection with murine PAI-1 cDNA). This study provides for the first time in vivo evidence for a dose-dependent effect of PAI-1 on tumor angiogenesis. Of great interest is the finding that PAI-1 produced by tumor cells, even at high concentration, did not overcome the absence of PAI-1 in the host, emphasizing the importance of the cellular source of PAI-1.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Almholt K, Nielsen BS, Frandsen TL, Brunner N, Dano K and Johnsen M . (2003). Oncogene, 22, 4389–4397.
Andreasen PA, Egelund R and Petersen HH . (2000). Cell Mol. Life Sci., 57, 25–40.
Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM and Noel A . (2001). J. Cell Biol., 152, 777–784.
Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D and Foidart JM . (1998). Nat. Med., 4, 923–928.
Curino A, Mitola DJ, Aaronson H, McMahon GA, Raja K, Keegan AD, Lawrence DA and Bugge TH . (2002). Oncogene, 21, 8830–8842.
Czekay RP, Aertgeerts K, Curriden SA and Loskutoff DJ . (2003). J. Cell Biol., 160, 781–791.
Deng G, Curriden SA, Hu G, Czekay RP and Loskutoff DJ . (2001). J. Cell Physiol., 189, 23–33.
Deng G, Curriden SA, Wang S, Rosenberg S and Loskutoff DJ . (1996). J. Cell Biol., 134, 1563–1571.
Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Noel A and Foidart JM . (2002). FASEB J., 16, 147–154.
Eitzman DT, Krauss JC, Shen T, Cui J and Ginsburg D . (1996). Blood, 87, 4718–4722.
Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL and Klijn JG . (2000). Cancer Res., 60, 636–643.
Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA and Castellino FJ . (2000). Cancer Res., 60, 5839–5847.
Isogai C, Laug WE, Shimada H, Declerck PJ, Stins MF, Durden DL, Erdreich-Epstein A and DeClerck YA . (2001). Cancer Res., 61, 5587–5594.
Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L and Andreasen PA . (1997). Exp. Cell Res., 232, 420–429.
Lambert V, Munaut C, Carmeliet P, Gerard RD, Declerck PJ, Gils A, Claes C, Foidart JM, Noel A and Rakic JM . (2003). Invest Ophthalmol. Vis. Sci., 44, 2791–2797.
Lambert V, Munaut C, Noel A, Frankenne F, Bajou K, Gerard R, Carmeliet P, Defresne MP, Foidart JM and Rakic JM . (2001). FASEB J., 15, 1021–1027.
Lijnen HR, Van Hoef B, Umans K and Collen D . (2004). J. THromb. Haemost., 2, 16–22.
Liu G, Shuman MA and Cohen RL . (1995). Int. J. Cancer, 60, 501–506.
Masson V, Devy L, Grignet-Debrus C, Bernt S, Bajou K, Blacher S, Roland G, Chang Y, Fong T, Carmeliet P, Foidart JM and Noel A . (2002). Biol. Proc. Online, 4, 24–31.
McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC and Lawrence DA . (2001). J. Biol. Chem., 276, 33964–33968.
Montesano R, Pepper MS, Mohle-Steinlein U, Risau W, Wagner EF and Orci L . (1990). Cell, 62, 435–445.
Pepper MS and Montesano R . (1990). Cell Differ. Dev., 32, 319–327.
Rakic JM, Maillard C, Jost M, Bajou K, Masson V, Devy L, Lambert V, Foidart JM and Noel A . (2003). Cell Mol. Life Sci., 60, 463–473.
Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S and Kwaan HC . (1995). J. Clin. Invest., 96, 2593–2600.
Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC and Lawrence DA . (2001). J. Biol. Chem., 276, 8135–8141.
Stephens RW, Brunner N, Janicke F and Schmitt M . (1998). Breast Cancer Res. Treat., 52, 99–111.
Acknowledgements
We thank Fabrice Olivier for his technical assistance. This work was supported by grants from the Communauté française de Belgique (Actions de Recherches Concertées), the Commission of European Communities (LSHC-CT-2003-503297), the Fonds National de la Recherche Scientifique (FNRS, Belgium), the Fédération Belge Contre le Cancer, the Fonds spéciaux de la Recherche (University of Liège), the Centre Anticancéreux près l'Université de Liège, the FB Assurances, the D.G.T.R.E. from the ‘Région Wallonne’, the Interuniversity Attraction Poles (I.U.A.P.) from the Federal Office for Scientific, Technical and Cultural Affairs (O.S.T.C., Brussels, Belgium).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bajou, K., Maillard, C., Jost, M. et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23, 6986–6990 (2004). https://doi.org/10.1038/sj.onc.1207859
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207859
Keywords
This article is cited by
-
The evaluation of six genes combined value in glioma diagnosis and prognosis
Journal of Cancer Research and Clinical Oncology (2023)
-
The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding
Cancer and Metastasis Reviews (2019)
-
Gene expression profiling of mesenteric lymph nodes from sheep with natural scrapie
BMC Genomics (2014)
-
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies
Breast Cancer Research (2014)
-
PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin
Nature Medicine (2014)